IGBA calls for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposal

2 March 2016

The European Biosimilars Group Appoints New Leadership Team With Sandoz’ Carol Lynch and Polpharma’s Klaus Martin

10 February 2016

Last week in Brussels, the European Biosimilar medicines Group (EBG […]

Generic and Biosimilar Medicines Essential for Italian Healthcare System

8 January 2016

Brussels – Generic and biosimilar medicines represent an essential opportunity to […]